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Abstract
Objective: The objective of this selective EBM was to investigate the question, “Is the
transcatheter aortic valve replacement associated with a decreased mortality rate when compared
to the surgical aortic valve replacement method in patients with severe aortic stenosis?”
Study Design: systematic review of 3 English language primary studies, published between
2013 and 2015.
Data Sources: Three Randomized Controlled Trials (RCT’s) published on or after 2010 were
selected based on their relevance to the proposed questions via PubMed. All three RCT’s
compared transcatheter aortic valve replacement (TAVR) vs. surgical aortic valve replacement
(SAVR) in patients with severe aortic stenosis.
Outcomes Measured: The outcomes measured in these studies include death from any cause at
1 year, quality of life, physical and social limitations, improvement of left ventricular ejection
fraction (LVEF) at 1 year following the procedure, and effect of LVEF on the outcome of the
procedure. This was accomplished using three separate techniques depending on the study using
either a chi-squared test, fischer exact test, or a combination of both tests.
Results: Thyregod et. al. found that the composite death rate from any cause, stroke or MI at 1
year was similar between TAVR vs. SAVR (13.1% vs 16.3%, repectively; p=0.43). Arnold et. al.
demonstrated that at 1 year the rates of favorable outcomes, as defined by this study, did not
differ significantly between TAVR vs. SAVR (58% vs 51%; p=0.143). Elmariah et. al. found
similar outcomes, death from any cause, stroke, or MI, were observed between TAVR and
SAVR in patients who had LVEF < 50% and those with a LVEF of >50% at 1 year (TAVR with
LVEF <50% vs LVEF > 50%: 25.9% vs 22.9%, p= 0.56; SAVR with LVEF < 50% vs LVEF >
50% 23.3% vs 25.2%, p=0.79). This study also observed similar outcomes between TAVR with
LVEF of < 50% and SAVR with LVEF < 50% at 2 years following the procedure (36.2% vs
31.3%, p=0.826)
Conclusions: Based on these studies, there is no significant decrease in the rate of overall
mortality, improvement of LVEF, or improvement of quality of life and symptoms between
patients who received TAVR vs SAVR. Further research should be conducted investigating the
long term follow up of these procedures to determine appropriate rates of mortality and
improvement of symptoms following these procedures.
Key Words: Transcatheter aortic valve replacement, surgical aortic valve replacement, severe
aortic stenosis, left ventricular dysfunction, mortality
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Introduction
Aortic Stenosis (AS) is defined as a narrowing of the aortic valve opening that results in
restricted blood flow from the left ventricle (LV) to the aorta. 2 Although some people may suffer
from congenital abnormalities, this condition most commonly develops from aging as calcium or
scar tissue damages the valve restricting its motion.4 The impeded motion of the aortic valve
leads to a decrease in blood flow from the LV to the aorta and, therefore, the rest of the
cardiovascular system. 2,3,4 This restriction of blood flow can result in many symptoms ranging
from shortness of breath, chest pain, syncope and decreased exercise tolerance.2 An estimated
610,000, or 1 out of every 4, people die of heart disease in the United States every year. 5 When
looking specifically at valvular disease, approximately 25% of the general population  65 years
of age are affected by aortic sclerosis. Of these, 2-9% suffer from aortic stenosis.6 According to
the Frankel Cardiovascular Center at Michigan Medicine, as many as 300,000 people in the US
are diagnosed each year with severe AS.3 The initial finding of AS is a harsh systolic,
crescendo/decrescendo mumur heard over the 2 nd right intercostal space. Accompanied with
symptoms of AS, this murmur warrants the use of further diagnostic testing. The diagnostic test
of choice is a transthoracic echocardiogram (TTE) with doppler.3 This test allows for the
assessment of aortic jet velocity, mean gradient, and aortic valve area, furthermore classifying
the severity of stenosis at the aortic valve.3 Severe AS is classified as an aortic jet velocity of > 4
m/sec, mean gradient > 40 mmHg, and an aortic valve area of < 1 cm2.3 According to a study
done by Osnabrugge et. al., there are approximately 290,000 elderly patients who meet these
criteria and are currently candidates for the TAVR procedure. They continued by stating that
approximately 27,000 patients become eligible for the procedure annually.
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Treatment of aortic stenosis depends on the severity of the disease and ranges from
lifestyle modifications to valvular replacement. For patients with mild to moderate disease,
lifestyle modifications (diet interventions, smoking cessation, exercise, etc.) and symptomatic
control with the use of long-term anti-coagulation, hypertensive treatments, and long term
antibiotics (prophylaxis for infective endocarditis) are the mainstay of treatment. However, in
patients with more severe AS valve replacement using either the TAVR or SAVR method are the
only definitive treatments.3,5 These treatments do not come without cost. According to the
American Heart Association (AHA), the estimated cost of a typical SAVR in the US ranges from
$80,000- $200,000.1,4 The cost of TAVR procedure in the US is typically higher due to the cost
of the device used in the procedure, $32,500.4
Due to the fact that there are no pharmacological treatments that can reverse the damage
to the valve that occurs in AS, the most definitive treatment for this disease is valve replacement.
There are currently two methods to replace a damaged aortic valve: SAVR and TAVR. The
surgical approach involves exposure via a midline sternotomy and the use of a cardiopulmonary
bypass machine to access the diseased valve. The transcatheter approach allows for replacement
of the valve via catheter using either iliofemoral, subclavian, or a direct aortic approach to gain
access to the aortic valve.3 In theory because this approach does not involve the use of
cardiopulmonary bypass or a sternotomy, recovery time, length of hospital stay, and rate of
overall mortality should be lower in patients who undergo the TAVR vs. SAVR.
Objective
The objective of this systematic review is to determine whether or not TAVR is
associated with a decreased rate of mortality when compared to SAVR in patients with severe
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AS. I selected three english language primary RCTs published between 2013 and 2015 for this
review.
The studies included in this review: Randomized clinical trial of Transcatheter vs.
Surgical Aortic Valve Replacement in patients with Severe AS by Thyregod et. al. 7(NOTION
Trial); Outcomes of Transcatheter and Surgical Aortic Valve Replacement in High-Risk patients
with AS and Left Ventricular Dysfunction by Elmariah et. al. 9 (PARTNER Trial Cohort A);
Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients with Severe
AS at increased Surgical Risk by Arnold et. al.10 (CoreValve Trial). Inclusion criteria for
selection of these studies were as follows: the comparison of TAVR vs. SAVR, a patient
population with severe AS, and a primary outcome of either overall mortality, improved LVEF,
or improved quality of life at least 1 year following the procedure. Studies were excluded from
this review if follow-up time was less than 1 year, if study conducted was not a RCT, the
population included in the study did not have a primary diagnosis of severe AS, if the study was
conducted prior to 2010, if the procedures assessed within the study did not include TAVR and
SAVR, or if the primary outcome addressed failed to include overall mortality. The inclusion
criteria for each study varied for each study but typically included severe AS with physical
limitations due to symptoms, NYHA class II + heart failure, and age 70 years. Exclusion
criteria for these studies varied as well but included patients who did not meet the inclusion
criteria, patients with another valvular or cardiac disease, prior cardiothoracic surgeries or
interventions, or those with other comorbidities including severe renal disease or neurological
events. Each study used a different type of measurement to determine clinical significance
between TAVR and SAVR. These methods will be discussed in further detail below. The
demographics and characteristics of the included studies are displayed in Table 1.
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Table 1- Demographics and Characteristics of included studies
Study
Arnold,
2015 (1)

Type
RCT

# of Pts
795

Age
76-90

Elmariah,
2013 (2)

RCT

699

76-90

Thyregod,
2015 (3)

RCT

280

79.1
(mean
age)

Inclusion
Severe
aortic
stenosis
with
substantial
functional
limitations
d/t heart
failure
symptoms
(NYHA
II+)
Severe
aortic
stenosis,
NYHA II+

70+ y/o,
severe
aortic
stenosis,
NYHA II+,
decreasing
LVEF

Exclusion
Pts who did
not meet the
inclusion
criteria (no
dx of Severe
aortic
stenosis/ not
receiving
interventions)

W/D
7

Interventions
SAVR
TAVR

Bicuspid or
noncalcified
aortic valve,
coronary
artery
disease,
LVEF of <
20%, aortic
annulus
diameter of <
18 or >
25mm,
severe mitral
or aortic
regurg (4+)
severe renal
insufficiency,
recent
cardiac/
neuro event
Another
severe heart
valve disease,
coronary
artery disease
requiring
intervention,
previous CT
surgery, MI/
CVA w/in 30
d

43

SAVR
TAVR

4 due to
mortality

SAVR
TAVR

4
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Methods
The following is a systematic review of three English language primary RCT’s published
on or after 2010 that were selected based on their relevance to the proposed questions via
PubMed. All three RCT’s compared TAVR vs. SAVR in patients with severe aortic stenosis.
Keywords used in the search include transcatheter aortic valve replacement, surgical aortic valve
replacement, severe aortic stenosis, left ventricular dysfunction, and mortality.
Outcomes Measured
In the PARTNER Trail, 699 patients from 25 sites who met the inclusion criteria,
determined by experienced surgeons, were randomly assigned to undergo either TAVR or
SAVR. The primary endpoint of this study was all-cause mortality at 1 year following the
procedure. Secondary end points included cardiovascular mortality, stroke, repeat
hospitalization, acute kidney injury, vascular complications, bleeding events, and NYHA
functional class. This study also evaluated the effect of LVEF on these outcomes. For this study
LV dysfunction was determined as an LVEF < 50% and improvement of LVEF was classified as
10% improvement in LVEF at 30 days. Analysis was performed using intention-to-treat data,
which began at the time of randomization, and as-treated data, beginning at the time of induction
of anesthesia. To measure the true effect of the included procedures, only as-treated data was
included in the statistical analysis of this study. Categorical variables were compared using
Fisher exact test. Continuous variables were compared using Student t-test. Survival curves for
time-to-event variables were compared using log-rank tests. Paired t tests were used to assess
changes in LVEF following the procedure. Other variables were measured in this study however,
they are not relevant to the question addressed in this systematic review. Statistical significance
was determined by a P value of <0.05.9

Singleton TAVR vs SAVR in Severe AS

6

In the CoreValve Trial, patients who met the inclusion criteria, as determined by 2
cardiac surgeons and 1 interventional cardiologist were randomly assigned in a 1:1 ratio to
treatment with either TAVR or SAVR. Disease specific and generic health status was assessed at
baseline, 1 month, 6 months, and 1 year following the procedure. Disease specific health status
was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ). This questionnaire
was a 23-item self-administered questionnaire that has been shown to be a reliable measure of
symptoms, functional status, and quality of life in patients with heart failure symptoms, including
those with symptomatic AS. Generic health status was evaluated with the Medical Outcomes
Study Short-Form 12 (SF-12) and the EuroQOL 5-dimension questionnaires. Acceptable and
favorable outcomes after TAVR were also measured using definitions that combined mortality
and quality of life into a single outcome. An acceptable outcome was defined as the presence of
all the following at 6 months after the procedure: alive, KCCQ score of 45 (roughly equal to
NYHA class III+), and stability or improvement of the patients KCCQ score from baseline to 6
months (decrease <10 points). A favorable outcome was defined as all the following at 1 year
following the procedure: alive, KCCQ score 60 (equal to NYHA class I-II), stability or
improvement of KCCQ score from baseline to 6 months (decrease < 10 points). Baseline
characteristics were compared using 2-sample Student t-test for continuous variables and x2tests for categorical variables. Follow-up health status scores at 1 month, 6 months, and 1 year
were compared using paired Student t-tests. Rates of acceptable and favorable outcomes at 6
months and 1 year were compared using x2-tests. In addition to the analysis of these variables
longitudinal random-effects growth curves were used to examine the relative effect of TAVR vs
AVR over time. Statistical significance was determined by a P value <0.05.10
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In the NOTION Trial, patients who met the inclusion criteria, as determined by a team
consisting of an imaging cardiologist, an interventional cardiologist, and a cardiac surgeon, were
randomized in a 1:1 ratio to treatment with either TAVR or SAVR. The primary outcomes
assessed in this study included death from any cause, stroke or MI at 1 year following the
procedure. The analysis for these outcomes was performed using logistic regression by adjusting
for age, trial site, and history of coronary artery disease (CAD) with a 2-sided alpha level of 5%.
Categorical variables were compared using the Fisher exact test or x 2-test. Continuous variables
were compared with the use of student t-tests.7
Results
In the study performed by Elmariah et. al., a total of 657 patients were included in the astreated cohort. Of these, 332 patients underwent TAVR and 304 underwent SAVR. 9 In both
groups a similar number of patients with LV dysfunction died at 30 days and at 1 year when
compared with those without LV dysfunction.9 In the TAVR group, 25.9% of patients with LV
dysfunction died by 1 year compared to 22.9% of patients with normal LV function (p=0.56).9 In
the SAVR group, 23.3% of patients with LV dysfunction died at 1 year compared to 25.2% of
patients with normal LV function (p=0.79).9 More importantly this study observed similar rates
of all-cause mortality at 2 years following the procedure in patients with LVEF < 50% who
underwent their assigned procedure (TAVR 36.2% vs. SAVR 31.3%, p=0.826).9 A similar trend
was observed in patients with normal LVEF at 2 years following their procedure (TAVR 31.8%
vs. SAVR 30.9%, p=0.826).9 Analysis for this systematic review was performed using the 2-year
data in the patient group classified as having LV dysfunction as these patients were more likely
to fit the inclusion criteria of this review. Table 2 contains the control event rate, experimental
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event rate, relative benefit increase, absolute benefit increase, and number needed to treat
analysis for this study.
Table 2: Analysis data comparing all-cause mortality at 2-years following TAVR vs. SAVR
as reported by the PARTNER Trial.

Patients

CER

EER

RBI

ABI

NNT

657

.313

.362

15.65%

4.9%

21

In the study conducted by Arnold et. al., 795 patients with severe symptomatic AS from
45 US centers met the inclusion criteria. Of those 394 were randomized to undergo TAVR and
401 were randomized to undergo SAVR. This study also stratified patients based on the site of
access used for the procedure.10 The access sites included either iliofemoral or non-iliofemoral
(subclavian or direct aortic) access.10 According to Arnold et. al. the iliofemoral TAVR (IFTAVR) group had a greater earlier improvement in health status when compared to the SAVR
group, with 16.7- point higher KCCQ overall summary scores at 1 month (CI=95%: 12.0 vs 21.3
pts, p= <0.001).10 This trend was not observed between these two groups at 6 months and 1
year.10 An acceptable outcome which, in this study, is a combination of survival status and health
status at 6 months occurred in 73% of TAVR patients vs 64% of SAVR patients (p=0.022). This
difference was confined to the IF-TAVR cohort (75% vs 63%, p=0.005), with no differences
between the two groups in patients with noniliofemoral (NIF) access. 10 At 1 year, the rates of
favorable outcomes did not differ significantly, regardless of access site (overall population
TAVR vs SAVR: 58% vs 51%, p=0.143).10 In concordance with the inclusion criteria of this
systematic review the data including the overall population collected at 1 year was analyzed.
Table 3 displays control event rate, experiment event rate, relative benefit increase, absolute
benefit increase, and number needed to treat.
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Table 3: Analysis data comparing favorable outcomes between TAVR and SAVR in the
overall population included in a study conducted by the CoreValve Trial.
Patients

CER

EER

RBI

ABI

NNT

795

.51

.58

13.73%

7.0%

15

In the study done by Thyregod et. al, 276 patients met the inclusion criteria and were
included in the as-treated cohort. Of those selected, 142 patients underwent TAVR and 134
patients underwent SAVR.7 Two patients who were assigned SAVR did not undergo this
procedure (1 treated with an apico-aortic conduit and 1 with apical TAVR); 3 TAVR patients
were converted to SAVR because of complications during the procedure. 7 No patients were lost
to follow-up in this study.7 In the intention-to-treat analysis, the primary outcome (composite
rate of death from any cause, stroke, or MI at 1 year) was similar between the 2 groups (13.1%
vs 16.3%, p=0.43).7 These results did not change for the as-treated analysis (11.3% vs 15.7%,
p=0.30).7 The as-treated data at 1-year found in this study was analyzed and the results are
represented in table 4. Table 4 includes control event rate, experiment event rate, relative benefit
increase, absolute benefit increase, and number needed to treat.
Table 4: Analysis data comparing the rate death from any cause, stroke or MI at 1-year
between TAVR and SAVR included in a study conducted by NOTION Trial.
Patients

CER

EER

RBI

ABI

NNT

276

.157

.113

-28.02%

-3.57%

-28

Discussion
Although these three studies had similar results, each one had additional findings and
limitations that should be mentioned within this review.
In addition to the results involving the primary outcome of their study, Elmariah et al.
found an association of LV dysfunction with 30-day cardiac death after SAVR and with an
increased risk of repeat hospitalization within the first year after TAVR. 9 This study observed

9
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substantial improvements in NYHA functional class after both TAVR and SAVR, regardless of
baseline LV function.9 However, no difference in the rate or degree of LV functional recovery
after either procedure was found.9 This study did have several limitations including the exclusion
of patients with severe LV dysfunction (<20% LVEF), and those with low gradient AS (aortic
valve gradient < 40 mmHg).9 The analyses done in this study were prone to survival selection
bias given that follow-up LVEF was only available in those who survived.9
Arnold et. al. also had additional findings to those surrounding their primary outcomes as
well as several limitations. When survival and quality of life outcomes were integrated into a
single metric, Arnold et. al. found that patients treated with TAVR were more likely to have an
acceptable outcome at 6 months when compared to those who underwent SAVR. A similar trend
was observed at the 1-year time frame. There were 2 important limitations to this study. The first
being the reported missing health status data over follow-up, particularly for the SAVR cohort.
The second being the fact that this trial was unblinded, which could have impacted the manner in
which the patients completed the health status assessments.
The NOTION Trial conducted by Thyregod et. al, had one of the lowest reported
mortality rates for transcatheter therapy, as well as low stroke rates when compared to previous
studies. Differences between the TAVR and SAVR were observed as procedure related
outcomes. TAVR patients experienced more conduction abnormalities requiring pacemaker
placement, and minor vascular complications. SAVR patients had more bleeding complications,
cardiogenic shock, acute kidney injury, and new-onset or worsening atrial fibrillation. Patients
who underwent SAVR also had a longer post-procedure hospital stay. One limitation of this
study was the sample size. The authors of this study state that the sample size may have been too
small to detect a potential difference in the effect of the treatment on the primary outcome. They

Singleton TAVR vs SAVR in Severe AS 11

also stated that several outcomes assessed were unblended, particularly which procedure was
conducted. Therefore, all outcomes addressed in this study, other than death, could be subject to
bias.
Conclusions
This systematic review was conducted to determine if there was a decreased rate of
mortality between patients with severe AS who received either TAVR or SAVR. After analyzing
the studies included in this review there is no statistical difference found in mortality rates
between the two groups. However, it is important to address one common finding between these
studies. Both the PARTNER trial and the CoreValve trial found an early improvement in health
status benefits at 30 days in the TAVR group. As stated above this trend was not observed at the
6 month and 1 year time mark. In both trials these early improvements were attributed to the less
invasive nature of the TAVR procedure when compared to SAVR.
Due to the recent introduction of the TAVR procedure further research is required to
investigate comparisons in long-term follow-up between TAVR and SAVR. This research should
focus on outcomes including overall mortality rate, symptomatic and quality of life
improvements, and improvements in LVEF in patients with severe AS. Further investigations
should be conducted in order to compare the efficacy of devices used in the TAVR procedure
(balloon expanding prosthesis vs self-expanding prosthesis).
Although no significant differences in mortality rates between the two procedures were
found, these studies did confirm both the efficacy and safety of TAVR in patients with severe
AS. Based on these studies, TAVR should be considered a feasible option in patients with severe
AS who are considered to be at risk for SAVR.
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